1 citations
,
October 2013 in “The Journal of Dermatology”
This letter to the editor discusses the immune response related to hairloss in a case of atypical drug-induced hypersensitivity syndrome but reports no new research findings.
This study found that activating hair follicle resident T cells in a human organ culture can induce an alopecia areata-like immune response, and that the drug farudodstat partially reduced this effect.
Chronic Telogen Effluvium can be managed by avoiding inflammatory foods, exercising, staying hydrated, and using supplements like krill oil, saw palmetto, or licorice root. Minoxidil is discouraged due to its cost and potential for worsening hairloss, while castor oil is recommended to strengthen hair roots and reduce shedding.
COVID and COVID vaccination can trigger hairloss, primarily telogen effluvium, due to stress and immune system activation. Proper diagnosis and addressing factors like nutrition and stress are crucial for recovery.
A 20-year-old male has been experiencing hairloss since age 15-16 and is using oral minoxidil, dutasteride, and ketoconazole shampoo, with previous use of oral finasteride and topical minoxidil. He has stabilized hairloss but seeks to rule out inflammatory or immune-related causes, considering a scalp biopsy, and is supplementing with vitamin D3, B12, and iron.
Topical roflumilast is effective for reducing inflammation in various scalp conditions like seborrheic dermatitis, psoriasis, and eczema, but not proven to stop scarring alopecia. Alternatives like apremilast and Vtama are also discussed for their anti-inflammatory benefits.
A permanent hairloss solution could involve reprogramming hair follicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.
a JAK inhibitor for alopecia areata and other autoimmune conditions
How does tofacitinib differ when used orally versus topically in hairloss treatment research?Oral tofacitinib acts on immune signalling throughout the body and has the stronger regrowth evidence in alopecia areata, alongside an FDA boxed warning; topical tofacitinib aims to act only on the scalp, but the human evidence is a handful of small compounded-formulation studies with no large randomized trial. Neither route is approved for hair loss, and regrowth generally reverses after treatment stops.
Tried everything and still getting bald patches? Procapil may help calm the immune responseProcapil is a cosmetic ingredient complex; laboratory studies of its individual ingredients report anti-inflammatory effects, but no published clinical trial has tested it in alopecia areata or any other immune-related hair loss. Spreading bald patches should be assessed by a dermatologist.
HMI-115: Frequently Asked Questions About HairLoss TreatmentHMI-115 is an investigational anti-prolactin-receptor antibody being trialled for androgenetic alopecia. It is not approved anywhere; its hair-loss evidence is a 16-person Phase 1b announced only by press release, plus a completed 192-man Phase 2 in China whose results are not yet published.